The Food and Drug Administration (FDA) of the Philippines has Approved Veredus Laboratories’ VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 for Commercial Use as an IVD Test for COVID-19

Singapore, June 15, 2020 – Veredus Laboratories Pte Ltd “Veredus” announced that the VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is now approved for commercial use as an In vitro Diagnostic (IVD) test in the Philippines by the Food and Drug Administration (FDA). This product was also authorised by the Singapore Health Sciences Authority (HSA) in early June for supply to hospitals and medical clinics for use on patients to diagnose COVID-19.

VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is a one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based IVD test intended for the qualitative detection of nucleic acid belonging to SARS-CoV-2.

“Veredus is very appreciative for the Philippines FDA to recognise and approve our RT-PCR test to be used as an IVD device in the country. We are motivated in reaching out beyond Singapore to introduce our diagnostic solutions in different parts of the world. With this, we hope to join the ecosystem and contribute vastly in the global fight against COVID-19” said Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.